脾脏和肝脏体积定量变化可预测原发性硬化性胆管炎患者的生存
本研究纳入89例有基线和随访肝脏影像及实验室数据的原发性硬化性胆管炎患者,评估脾脏和肝脏体积变化对生存的预测价值。脾脏体积变化和左叶与全肝体积比(L/T)变化是仅有的在有无不良结局患者间差异有统计学意义的体积参数,脾脏体积变化<50 ml和L/T变化<0.04的患者36个月无移植生存概率更高。
要点
- 脾脏体积变化<50 ml者36个月无移植生存率59.1%,≥50 ml者11.9%,AUC=0.731。
- L/T变化<0.04者36个月无移植生存率61.3%,≥0.04者13.8%,AUC=0.638。
- 脾脏体积和L/T变化均低于界值时36个月无移植生存率76.8%,高于仅一项或两项均不低于界值者。
核心结论
- 脾脏体积变化和L/T变化可能是预测原发性硬化性胆管炎患者无移植生存的有用生物标志物。
研究设计与样本
- 经机构审查委员会批准的单中心研究,纳入2000年至2018年间89例有基线和随访肝脏影像检查及实验室数据的原发性硬化性胆管炎患者;比较有无不良结局(肝移植、移植等待名单和死亡)患者间脾脏体积、全肝及肝叶体积、肝叶与全肝体积比的变化;采用受试者工作特征(ROC)和Kaplan-Meier分析确定预测结局的体积阈值并展示阈值对生存的预测。
诊断标准与关键数值
- 有无不良结局患者间变化差异有统计学意义的体积参数仅为脾脏体积(p<0.001)和左叶与全肝体积比(L/T;p=0.025);脾脏体积变化<50 ml者36个月无移植生存概率59.1%,≥50 ml者11.9%(AUC=0.731);L/T变化<0.04者36个月无移植生存概率61.3%,≥0.04者13.8%(AUC=0.638);脾脏体积和L/T变化均低于界值者36个月无移植生存概率76.8%,仅一项或两项均不低于界值者分别为36.7%和15%(p=0.001)。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To assess the value of quantitative spleen and liver volume changes in predicting the survival of patients with primary sclerosing cholangitis (PSC).
MATERIALS AND METHODS: This institutional review board-approved single-centre study included 89 PSC patients with baseline and follow-up liver imaging studies and laboratory data between 2000 and 2018. Change in spleen, total and lobar liver volumes, and lobar-to-total liver volume ratio was compared between patients with and without adverse outcome (liver transplantation, transplant waiting list, and death). Receiver operating characteristic (ROC) and Kaplan-Meier analysis were performed to identify the volumetric threshold for prediction of outcome and show how these thresholds predict survival, respectively. A p-value of <0.05 was considered statistically significant.
RESULTS: The present cohort included 53 men (60%), with mean age of 42 years at baseline. The only volumetric parameters with significant differences in change between patients with and without adverse outcome were spleen volume (p<0.001) and left-to-total liver volume ratio (L/T; p=0.025). The probability of transplant-free survival at 36 months was 59.1% versus 11.9% for patients with spleen volume change <50 ml versus ≥50 ml, respectively (AUC=0.731); and 61.3% versus 13.8% for patients with L/T change <0.04 versus ≥0.04, respectively (AUC=0.638). The patients with changes below the cut-off in both spleen volume and L/T, had a higher probability of transplant-free survival at 36 months (76.8%), compared to those with change at or below the cut-offs in one or both of these two parameters (36.7%, 15%, respectively; p=0.001).
CONCLUSION: Spleen volume change and L/T change might be useful biomarkers for prediction of transplant-free survival in patients with PSC.
引用
- Khoshpouri P, Hazhirkarzar B, Ameli S, et al. Quantitative spleen and liver volume changes predict survival of patients with primary sclerosing cholangitis. Clin Radiol. 2019. PMID: 31239109. doi:10.1016/j.crad.2019.05.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。